carbamates has been researched along with Innate Inflammatory Response in 64 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Given that the pharmacological or genetic inactivation of fatty acid amide hydrolase (FAAH) counteracts pain and inflammation, and on the basis of the established involvement of transient receptor potential vanilloid type-1 (TRPV1) channels in inflammatory pain, we tested the capability of a dual FAAH/TRPV1 blocker, N-arachidonoyl-serotonin (AA-5-HT), to relieve oedema and pain in a model of acute inflammation, and compared its efficacy with that of a single FAAH inhibitor (URB597) or TRPV1 antagonist (capsazepine)." | 7.76 | The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. ( Bettoni, I; Comelli, F; Costa, B; Di Marzo, V; Giagnoni, G; Petrosino, S, 2010) |
| " We compared the effects of two insulin secretagogues, repaglinide and glyburide, known to have different efficacy on postprandial hyperglycemia, on carotid intima-media thickness (CIMT) and markers of systemic vascular inflammation in type 2 diabetic patients." | 5.11 | Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. ( Esposito, K; Giugliano, D; Marfella, R; Nappo, F, 2004) |
| "The pharmacological inhibition of anandamide (AEA) hydrolysis by fatty acid amide hydrolase (FAAH) attenuates pain in animal models of osteoarthritis (OA) but has failed in clinical trials." | 3.81 | A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis. ( Binkowski, M; Czaja, M; Di Marzo, V; Kolosowska, N; Makuch, W; Malek, N; Morera, E; Mrugala, M; Przewlocka, B; Starowicz, K, 2015) |
| "Given that the pharmacological or genetic inactivation of fatty acid amide hydrolase (FAAH) counteracts pain and inflammation, and on the basis of the established involvement of transient receptor potential vanilloid type-1 (TRPV1) channels in inflammatory pain, we tested the capability of a dual FAAH/TRPV1 blocker, N-arachidonoyl-serotonin (AA-5-HT), to relieve oedema and pain in a model of acute inflammation, and compared its efficacy with that of a single FAAH inhibitor (URB597) or TRPV1 antagonist (capsazepine)." | 3.76 | The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. ( Bettoni, I; Comelli, F; Costa, B; Di Marzo, V; Giagnoni, G; Petrosino, S, 2010) |
| " Here, we describe the anti-COVID-19 potential of PTC299, an orally bioavailable compound that is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), the rate-limiting enzyme of the de novo pyrimidine nucleotide biosynthesis pathway." | 1.62 | The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. ( Bavari, S; Cao, L; Cintron-Lue, K; Colacino, JM; Goodwin, E; Graci, JD; Jacobson, A; Kong, R; Luban, J; Mühlberger, E; Naryshkin, NA; O'Keefe, K; Paessler, S; Peltz, SW; Pykett, M; Sattler, RA; Soloveva, V; Strambio-De-Castillia, C; Suder, EL; Trotta, C; Wang, Y; Weetall, M; Welch, EM, 2021) |
| "Airway inflammation was induced by intranasal (i." | 1.56 | The effects of fatty acid amide hydrolase and monoacylglycerol lipase inhibitor treatments on lipopolysaccharide-induced airway inflammation in mice. ( Abohalaka, R; Bozkurt, TE; Nemutlu, E; Onder, SC; Sahin-Erdemli, I, 2020) |
| "Joint inflammation was also measured in a separate cohort of animals treated on day 1 with either saline or the FAAH inhibitor URB597 (0." | 1.46 | Early blockade of joint inflammation with a fatty acid amide hydrolase inhibitor decreases end-stage osteoarthritis pain and peripheral neuropathy in mice. ( Krustev, E; McDougall, JJ; Muley, MM; Philpott, HT; Reid, A, 2017) |
| "SA-57 dose-dependently reversed mechanical allodynia in the constriction injury (CCI) of the sciatic nerve model of neuropathic pain and carrageenan inflammatory pain model." | 1.46 | The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. ( Abdullah, RA; Cabrera, R; Cravatt, BF; Ghosh, S; Lichtman, AH; Maldonado, RL; Mustafa, M; Niphakis, MJ; Wilkerson, JL, 2017) |
| " We evaluated the impact of TLR and Notch signaling on ERD in a murine model by administering CpG, an agonist of TLR9, in combination with L685,458, an inhibitor of Notch signaling during FI-RSV immunization." | 1.46 | CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells in Lung ( Deng, Y; Du, X; Hai, Y; Li, H; Li, N; Li, W; Wei, L; Yin, W; Zeng, R; Zhang, L; Zhang, Z; Zheng, B, 2017) |
| " Whether repeated dosing would achieve greater protection remains to be examined." | 1.42 | Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury. ( Impastato, RA; Katz, PS; Molina, PE; Rogers, EK; Sulzer, JK; Teng, SX, 2015) |
| "Visceral pain is strongly associated with inflammation and distension of the gut." | 1.42 | The effect of FAAH, MAGL, and Dual FAAH/MAGL inhibition on inflammatory and colorectal distension-induced visceral pain models in Rodents. ( Bagci, S; Dogrul, A; Gulsen, M; Ilkaya, F; Sakin, YS; Seyrek, M; Ulas, UH, 2015) |
| "Effects of pre-treatment with a single dose, versus 4 day repeated dosing with the selective FAAH inhibitor, URB597 (i." | 1.38 | Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. ( Alexander, SP; Barrett, DA; Bennett, AJ; Burston, J; Chapman, V; Kendall, DA; Norris, LM; Okine, BN; Patel, A; Woodhams, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (10.94) | 29.6817 |
| 2010's | 39 (60.94) | 24.3611 |
| 2020's | 10 (15.63) | 2.80 |
| Authors | Studies |
|---|---|
| Kaya-Tilki, E | 1 |
| Dikmen, M | 1 |
| Wang, DP | 1 |
| Kang, K | 1 |
| Sun, J | 1 |
| Lin, Q | 1 |
| Lv, QL | 1 |
| Hai, J | 1 |
| Pawelec, P | 1 |
| Sypecka, J | 1 |
| Zalewska, T | 1 |
| Ziemka-Nalecz, M | 1 |
| Yang, GX | 1 |
| Huang, Y | 1 |
| Zheng, LL | 1 |
| Zhang, L | 2 |
| Su, L | 1 |
| Wu, YH | 1 |
| Li, J | 1 |
| Zhou, LC | 1 |
| Huang, J | 1 |
| Tang, Y | 1 |
| Wang, R | 1 |
| Ma, L | 1 |
| Abdel Moneim, A | 1 |
| Suleiman, HA | 1 |
| Mahmoud, B | 2 |
| Mabrouk, D | 1 |
| Zaky, MY | 1 |
| Yang, Q | 1 |
| Li, S | 1 |
| Zhou, Z | 1 |
| Fu, M | 1 |
| Yang, X | 1 |
| Hao, K | 1 |
| Liu, Y | 1 |
| Abohalaka, R | 1 |
| Bozkurt, TE | 1 |
| Nemutlu, E | 1 |
| Onder, SC | 1 |
| Sahin-Erdemli, I | 1 |
| Peng, K | 1 |
| Liu, H | 1 |
| Yan, B | 1 |
| Meng, XW | 1 |
| Song, SY | 1 |
| Ji, FH | 1 |
| Xia, Z | 1 |
| Chila-Moreno, L | 1 |
| Rodríguez, LS | 1 |
| Bautista-Molano, W | 1 |
| Bello-Gualtero, JM | 1 |
| Ramos-Casallas, A | 1 |
| Romero-Sánchez, C | 1 |
| Luban, J | 1 |
| Sattler, RA | 1 |
| Mühlberger, E | 1 |
| Graci, JD | 1 |
| Cao, L | 1 |
| Weetall, M | 1 |
| Trotta, C | 1 |
| Colacino, JM | 1 |
| Bavari, S | 1 |
| Strambio-De-Castillia, C | 1 |
| Suder, EL | 1 |
| Wang, Y | 1 |
| Soloveva, V | 1 |
| Cintron-Lue, K | 1 |
| Naryshkin, NA | 1 |
| Pykett, M | 1 |
| Welch, EM | 1 |
| O'Keefe, K | 1 |
| Kong, R | 1 |
| Goodwin, E | 1 |
| Jacobson, A | 1 |
| Paessler, S | 1 |
| Peltz, SW | 1 |
| Karwad, MA | 1 |
| Couch, DG | 1 |
| Theophilidou, E | 1 |
| Sarmad, S | 1 |
| Barrett, DA | 2 |
| Larvin, M | 2 |
| Wright, KL | 2 |
| Lund, JN | 1 |
| O'Sullivan, SE | 2 |
| McDougall, JJ | 2 |
| Muley, MM | 1 |
| Philpott, HT | 1 |
| Reid, A | 2 |
| Krustev, E | 2 |
| Fukuda, T | 1 |
| Goto, R | 1 |
| Kiho, T | 1 |
| Ueda, K | 1 |
| Muramatsu, S | 1 |
| Hashimoto, M | 1 |
| Aki, A | 1 |
| Watanabe, K | 1 |
| Tanaka, N | 1 |
| Burchill, MA | 1 |
| Roby, JA | 1 |
| Crochet, N | 1 |
| Wind-Rotolo, M | 1 |
| Stone, AE | 1 |
| Edwards, MG | 1 |
| Dran, RJ | 1 |
| Kriss, MS | 1 |
| Gale, M | 1 |
| Rosen, HR | 1 |
| Sasso, O | 1 |
| Summa, M | 1 |
| Armirotti, A | 1 |
| Pontis, S | 1 |
| De Mei, C | 1 |
| Piomelli, D | 2 |
| Milan, M | 1 |
| Pace, V | 1 |
| Maiullari, F | 1 |
| Chirivì, M | 1 |
| Baci, D | 1 |
| Maiullari, S | 1 |
| Madaro, L | 1 |
| Maccari, S | 1 |
| Stati, T | 1 |
| Marano, G | 1 |
| Frati, G | 1 |
| Puri, PL | 1 |
| De Falco, E | 1 |
| Bearzi, C | 1 |
| Rizzi, R | 1 |
| Flannery, LE | 1 |
| Kerr, DM | 1 |
| Finn, DP | 1 |
| Roche, M | 1 |
| Manterola, A | 1 |
| Bernal-Chico, A | 1 |
| Cipriani, R | 1 |
| Ruiz, A | 1 |
| Pérez-Samartín, A | 1 |
| Moreno-Rodríguez, M | 1 |
| Hsu, KL | 1 |
| Cravatt, BF | 2 |
| Brown, JM | 1 |
| Rodríguez-Puertas, R | 1 |
| Matute, C | 1 |
| Mato, S | 1 |
| Jin, C | 1 |
| Zeng, Z | 1 |
| Wang, C | 1 |
| Luo, T | 1 |
| Wang, S | 1 |
| Zhou, J | 1 |
| Ni, Y | 1 |
| Fu, Z | 1 |
| Jin, Y | 1 |
| Azrad, M | 1 |
| Zeineh, N | 1 |
| Weizman, A | 2 |
| Veenman, L | 1 |
| Gavish, M | 2 |
| Monga, S | 1 |
| Nagler, R | 1 |
| Amara, R | 1 |
| Tanaka, M | 1 |
| Yagyu, K | 1 |
| Sackett, S | 1 |
| Zhang, Y | 1 |
| Alhouayek, M | 1 |
| Masquelier, J | 1 |
| Cani, PD | 1 |
| Lambert, DM | 1 |
| Muccioli, GG | 1 |
| Shi, J | 1 |
| van Veelen, PA | 1 |
| Mahler, M | 1 |
| Janssen, GM | 1 |
| Drijfhout, JW | 1 |
| Huizinga, TW | 1 |
| Toes, RE | 1 |
| Trouw, LA | 1 |
| Döring, G | 2 |
| Bragonzi, A | 1 |
| Paroni, M | 1 |
| Aktürk, FF | 1 |
| Cigana, C | 1 |
| Schmidt, A | 1 |
| Gilpin, D | 1 |
| Heyder, S | 1 |
| Born, T | 1 |
| Smaczny, C | 1 |
| Kohlhäufl, M | 1 |
| Wagner, TO | 1 |
| Loebinger, MR | 1 |
| Bilton, D | 1 |
| Tunney, MM | 1 |
| Elborn, JS | 1 |
| Pier, GB | 1 |
| Konstan, MW | 2 |
| Ulrich, M | 1 |
| Bitencourt, CS | 1 |
| Bessi, VL | 1 |
| Huynh, DN | 1 |
| Ménard, L | 1 |
| Lefebvre, JS | 1 |
| Lévesque, T | 1 |
| Hamdan, L | 1 |
| Sohouhenou, F | 1 |
| Faccioli, LH | 1 |
| Borgeat, P | 1 |
| Marleau, S | 1 |
| Heltshe, SL | 1 |
| Lands, LC | 1 |
| Hilliard, KA | 1 |
| Koker, P | 1 |
| Bhattacharya, S | 1 |
| Staab, A | 1 |
| Hamilton, A | 1 |
| Hayashi, H | 1 |
| Iwata, M | 1 |
| Tsuchimori, N | 1 |
| Matsumoto, T | 1 |
| Zeltz, C | 1 |
| Gullberg, D | 1 |
| Katz, PS | 1 |
| Sulzer, JK | 1 |
| Impastato, RA | 1 |
| Teng, SX | 1 |
| Rogers, EK | 1 |
| Molina, PE | 1 |
| Gilet, M | 1 |
| Eutamene, H | 1 |
| Han, H | 1 |
| Kim, HW | 1 |
| Bueno, L | 1 |
| Malek, N | 1 |
| Mrugala, M | 1 |
| Makuch, W | 1 |
| Kolosowska, N | 1 |
| Przewlocka, B | 1 |
| Binkowski, M | 1 |
| Czaja, M | 1 |
| Morera, E | 1 |
| Di Marzo, V | 2 |
| Starowicz, K | 1 |
| Sakin, YS | 1 |
| Dogrul, A | 1 |
| Ilkaya, F | 1 |
| Seyrek, M | 1 |
| Ulas, UH | 1 |
| Gulsen, M | 1 |
| Bagci, S | 1 |
| Feng, L | 2 |
| Zhu, MM | 1 |
| Bu, WQ | 1 |
| Wang, CF | 1 |
| Zheng, ZG | 1 |
| Wang, RS | 1 |
| Jia, XB | 1 |
| Zhu, Q | 2 |
| Helali, I | 1 |
| Ferchichi, S | 1 |
| Maaouia, A | 1 |
| Aouni, M | 1 |
| Harizi, H | 1 |
| Podbielska, M | 1 |
| Das, A | 1 |
| Smith, AW | 1 |
| Chauhan, A | 1 |
| Ray, SK | 1 |
| Inoue, J | 1 |
| Azuma, M | 1 |
| Nozaki, K | 1 |
| Hogan, EL | 1 |
| Banik, NL | 1 |
| Wilkerson, JL | 1 |
| Ghosh, S | 1 |
| Mustafa, M | 1 |
| Abdullah, RA | 1 |
| Niphakis, MJ | 1 |
| Cabrera, R | 1 |
| Maldonado, RL | 1 |
| Lichtman, AH | 1 |
| Rivera-Arconada, I | 1 |
| Vicente-Baz, J | 1 |
| Lopez-Garcia, JA | 1 |
| Li, H | 2 |
| Hai, Y | 1 |
| Yin, W | 1 |
| Li, W | 1 |
| Zheng, B | 1 |
| Du, X | 1 |
| Li, N | 1 |
| Zhang, Z | 1 |
| Deng, Y | 1 |
| Zeng, R | 1 |
| Wei, L | 1 |
| Zhang, T | 2 |
| Tang, M | 1 |
| Zhang, S | 1 |
| Hu, Y | 1 |
| Xue, Y | 1 |
| Pu, Y | 1 |
| Sagar, DR | 1 |
| Kendall, DA | 2 |
| Chapman, V | 2 |
| Costa, B | 2 |
| Bettoni, I | 1 |
| Petrosino, S | 1 |
| Comelli, F | 2 |
| Giagnoni, G | 1 |
| Xu, W | 1 |
| Wu, Y | 1 |
| Bi, Y | 1 |
| Tan, L | 1 |
| Gan, Y | 1 |
| Wang, K | 1 |
| RENNIE, JW | 1 |
| Gumieniczek, A | 1 |
| Komsta, L | 1 |
| Chehab, MR | 1 |
| Alhamoruni, A | 1 |
| Linley, JE | 1 |
| Pettinger, L | 1 |
| Huang, D | 1 |
| Gamper, N | 1 |
| Okine, BN | 1 |
| Norris, LM | 1 |
| Woodhams, S | 1 |
| Burston, J | 1 |
| Patel, A | 1 |
| Alexander, SP | 1 |
| Bennett, AJ | 1 |
| Ayciriex, S | 1 |
| Regazzetti, A | 1 |
| Gaudin, M | 1 |
| Prost, E | 1 |
| Dargère, D | 1 |
| Massicot, F | 1 |
| Auzeil, N | 1 |
| Laprévote, O | 1 |
| Zhu, M | 1 |
| Zhang, M | 1 |
| Jia, X | 1 |
| Cheng, X | 1 |
| Ding, S | 1 |
| BUECH, O | 2 |
| Esposito, K | 1 |
| Giugliano, D | 1 |
| Nappo, F | 1 |
| Marfella, R | 1 |
| Young, EM | 1 |
| Considine, RV | 1 |
| Sattler, FR | 1 |
| Deeg, MA | 1 |
| Buchanan, TA | 1 |
| Degawa-Yamauchi, M | 1 |
| Shankar, S | 1 |
| Edmondson-Melançon, H | 1 |
| Hernandez, J | 1 |
| Dubé, MP | 1 |
| Holt, S | 1 |
| Fowler, CJ | 1 |
| Jayamanne, A | 1 |
| Greenwood, R | 1 |
| Mitchell, VA | 1 |
| Aslan, S | 1 |
| Vaughan, CW | 1 |
| Wang, Z | 1 |
| Nicholls, SJ | 1 |
| Rodriguez, ER | 1 |
| Kummu, O | 1 |
| Hörkkö, S | 1 |
| Barnard, J | 1 |
| Reynolds, WF | 1 |
| Topol, EJ | 1 |
| DiDonato, JA | 1 |
| Hazen, SL | 1 |
| Rader, DJ | 1 |
| Ischiropoulos, H | 1 |
| Mimura, T | 1 |
| Nakajima, H | 1 |
| Kohama, Y | 1 |
| Okabe, M | 1 |
| Tsujikawa, K | 1 |
| Itoh, S | 1 |
| Ohmura, T | 1 |
| Iwai, M | 1 |
| Yokoyama, K | 1 |
| Cordeiro, RS | 1 |
| Martins, MA | 1 |
| Silva, PM | 1 |
| Faria Neto, HC | 1 |
| Castanheira, JR | 1 |
| Vargaftig, BB | 1 |
| Depreux, P | 1 |
| Marcincal-Lefebvre, A | 1 |
| Lykke, AW | 1 |
| Willoughby, DA | 1 |
| Kosche, ER | 1 |
| Shimamoto, T | 1 |
| Maezawa, H | 1 |
| Yamazaki, H | 1 |
| Atsumi, T | 1 |
| Fujita, T | 1 |
| Ishioka, T | 1 |
| Sunaga, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Expression of Inflammasomes in HCV Patients Before and After Treatment[NCT04244383] | Phase 4 | 50 participants (Anticipated) | Interventional | 2020-01-31 | Not yet recruiting | ||
| Osteoarthritis of the Knee Pain Study Using CBD and THC in Rapidly Dissolvable Sublingual Tablet[NCT04195269] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-04-20 | Recruiting | ||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)[NCT03819790] | Phase 4 | 119 participants (Actual) | Interventional | 2018-10-02 | Completed | ||
| Genetic, Epigenetic, Psychosocial, and Biological Determinants of Post-surgical Pain After Pectus or Spine Surgery[NCT04031716] | 600 participants (Anticipated) | Interventional | 2018-07-06 | Enrolling by invitation | |||
| Clinical Follow-up of Anti-Carbamylated Antibody Status in Rheumatoid Arthritis Patients at 6, 12 and 18 Months[NCT02958319] | 278 participants (Actual) | Observational | 2016-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
"To explore the clinical differences in activity indexes (DAS28-ESR) at 6, 12 and 18 months of follow-up according the anti-CarP status.~The DAS28 is a composite score derived from 4 measures, one of them can be the erythrocyte sedimentation rate (ESR). We will be using the DAS28-ESR version. To calculate the DAS28-ESR the rheumatologist or specialist nurse will:- count the number of swollen joints (out of the 28), count the number of tender joints (out of the 28), take blood to measure ESR, ask participants to make a 'global assessment of health' (indicated by marking a 10 cm line between very good and very bad).~DAS28-ESR is calculated with classic calculators and resulting values are interpreted as follows:~<2.6: disease remission 2.6 - 3.2: low disease activity 3.2 - 5.1: moderate disease activity >5.1: high disease activity" (NCT02958319)
Timeframe: 6, 12 and 18 Months
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 6 MONTHS | 12 MONTHS | 18 MONTHS | |
| Anti P Carb Negative RA Patients | 3.75 | 3.59 | 3.65 |
| Anti P Carb Positive RA Patients | 3.72 | 3.69 | 3.77 |
2 reviews available for carbamates and Innate Inflammatory Response
| Article | Year |
|---|---|
Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies.
Topics: Animals; Antibodies; Autoimmunity; Carbamates; Humans; Inflammation; Protein Processing, Post-Transl | 2014 |
Post-translational modifications of integrin ligands as pathogenic mechanisms in disease.
Topics: Amidohydrolases; Carbamates; Cell Adhesion; Diabetes Mellitus; Extracellular Matrix Proteins; Fibron | 2014 |
5 trials available for carbamates and Innate Inflammatory Response
| Article | Year |
|---|---|
Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Biomarkers; Carbamates; Diabetes Mellitus, Type 2; Female; Genotype; Glycat | 2020 |
A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.
Topics: Adolescent; Adult; Amidines; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Carbamates; Chi | 2014 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy.
Topics: Adult; Biomarkers; Blood Glucose; Carbamates; Drug Therapy, Combination; Female; Fibrinolysis; Furan | 2004 |
Pyridinolcarbamate, a bradykinin antagonist in veins. A preliminary report on pharmacologic and clinical observations.
Topics: Adams-Stokes Syndrome; Aged; Animals; Bradykinin; Carbamates; Coronary Disease; Electrocardiography; | 1966 |
57 other studies available for carbamates and Innate Inflammatory Response
| Article | Year |
|---|---|
Neuroprotective effects of some epigenetic modifying drugs' on Chlamydia pneumoniae-induced neuroinflammation: A novel model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Carbamates; Chlamydophila Infections; Chlamydophila pneumo | 2021 |
URB597 and Andrographolide Improve Brain Microvascular Endothelial Cell Permeability and Apoptosis by Reducing Oxidative Stress and Inflammation Associated with Activation of Nrf2 Signaling in Oxygen-Glucose Deprivation.
Topics: Anti-Inflammatory Agents; Apoptosis; Benzamides; Brain; Carbamates; Diterpenes; Endothelial Cells; G | 2022 |
Analysis of Givinostat/ITF2357 Treatment in a Rat Model of Neonatal Hypoxic-Ischemic Brain Damage.
Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Brain; Carbamates; Cytokines; Humans; Hydroxamic Aci | 2022 |
Design, synthesis and evaluation of diosgenin carbamate derivatives as multitarget anti-Alzheimer's disease agents.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; A | 2020 |
HDAC6 inhibitor Cay10603 inhibits high glucose-induced oxidative stress, inflammation and apoptosis in retinal pigment epithelial cells via regulating NF-κB and NLRP3 inflammasome pathway.
Topics: Apoptosis; Carbamates; Epithelial Cells; Glucose; Histone Deacetylase Inhibitors; Humans; Inflammaso | 2020 |
The effects of fatty acid amide hydrolase and monoacylglycerol lipase inhibitor treatments on lipopolysaccharide-induced airway inflammation in mice.
Topics: Amidohydrolases; Animals; Arachidonic Acids; Benzamides; Benzodioxoles; Carbamates; Cytokines; Endoc | 2020 |
Inhibition of cathepsin S attenuates myocardial ischemia/reperfusion injury by suppressing inflammation and apoptosis.
Topics: Animals; Animals, Newborn; Apoptosis; Benzopyrans; Carbamates; Cardiotonic Agents; Cathepsins; Disea | 2021 |
Anti-carbamylated protein and peptide antibodies as potential inflammatory joint biomarkers in the relatives of rheumatoid arthritis patients.
Topics: Adult; Arthritis, Rheumatoid; Autoantibodies; Biomarkers; Carbamates; Cross-Sectional Studies; Femal | 2020 |
The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines.
Topics: Animals; Antiviral Agents; Carbamates; Carbazoles; Chlorocebus aethiops; COVID-19 Drug Treatment; Cy | 2021 |
The role of CB
Topics: Amidohydrolases; Arachidonic Acids; Benzamides; Benzodioxoles; Caco-2 Cells; Carbamates; Colorectal | 2017 |
Early blockade of joint inflammation with a fatty acid amide hydrolase inhibitor decreases end-stage osteoarthritis pain and peripheral neuropathy in mice.
Topics: Amidohydrolases; Animals; Arthralgia; Benzamides; Carbamates; Inflammation; Knee Joint; Male; Mice; | 2017 |
Discovery of DS79182026: A potent orally active hepcidin production inhibitor.
Topics: Administration, Oral; Animals; Benzoxazoles; Carbamates; Gene Expression Regulation; Half-Life; Hepc | 2017 |
Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy.
Topics: Aged; Animals; Antiviral Agents; Benzazepines; Carbamates; Disease Models, Animal; Female; Gene Expr | 2017 |
The N-Acylethanolamine Acid Amidase Inhibitor ARN077 Suppresses Inflammation and Pruritus in a Mouse Model of Allergic Dermatitis.
Topics: Amides; Amidohydrolases; Animals; Carbamates; Dermatitis, Allergic Contact; Dinitrofluorobenzene; Di | 2018 |
Givinostat reduces adverse cardiac remodeling through regulating fibroblasts activation.
Topics: Animals; Apoptosis; Carbamates; Endothelium; Epithelium; Female; Fibroblasts; Fibrosis; Gene Express | 2018 |
FAAH inhibition attenuates TLR3-mediated hyperthermia, nociceptive- and anxiety-like behaviour in female rats.
Topics: Amidohydrolases; Animals; Anxiety; Benzamides; Carbamates; Central Nervous System Agents; Enzyme Inh | 2018 |
Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis.
Topics: Animals; Benzoates; Biphenyl Compounds; Brain; Calcium; Carbamates; Cells, Cultured; Encephalomyelit | 2018 |
Insights into a Possible Mechanism Underlying the Connection of Carbendazim-Induced Lipid Metabolism Disorder and Gut Microbiota Dysbiosis in Mice.
Topics: Animals; Benzimidazoles; Blood Glucose; Body Weight; Carbamates; Cytokines; Dysbiosis; Fungicides, I | 2018 |
The TSPO Ligands 2-Cl-MGV-1, MGV-1, and PK11195 Differentially Suppress the Inflammatory Response of BV-2 Microglial Cell to LPS.
Topics: Animals; Blotting, Western; Carbamates; Cell Line; Inflammation; Isoquinolines; Lipopolysaccharides; | 2019 |
Inhibitory Effects of the Two Novel TSPO Ligands 2-Cl-MGV-1 and MGV-1 on LPS-induced Microglial Activation.
Topics: Animals; Carbamates; Cell Line; Cytokines; Inflammation; Ligands; Lipopolysaccharides; Microglia; Qu | 2019 |
Anti-Inflammatory Effects by Pharmacological Inhibition or Knockdown of Fatty Acid Amide Hydrolase in BV2 Microglial Cells.
Topics: Amidohydrolases; Animals; Anti-Inflammatory Agents; Benzamides; Carbamates; Cell Line; Cyclooxygenas | 2019 |
Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6.
Topics: Animals; Anti-Inflammatory Agents; Arachidonic Acids; Biphenyl Compounds; Carbamates; Cell Line; Cel | 2013 |
BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs.
Topics: Adult; Amidines; Animals; Anti-Inflammatory Agents; Bacteremia; Carbamates; Cystic Fibrosis; Disease | 2014 |
Cooperative role of endogenous leucotrienes and platelet-activating factor in ischaemia-reperfusion-mediated tissue injury.
Topics: Amidines; Animals; Azepines; Biological Assay; Carbamates; Dermis; Disease Models, Animal; Extravasa | 2013 |
Activation of peripheral KCNQ channels attenuates inflammatory pain.
Topics: Animals; Anthracenes; Anticonvulsants; Benzamides; Carbamates; Disease Models, Animal; Electric Stim | 2014 |
Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury.
Topics: Animals; Arachidonic Acids; Benzamides; Benzodioxoles; Blood-Brain Barrier; Blotting, Western; Brain | 2015 |
Tapping into the endocannabinoid system to ameliorate acute inflammatory flares and associated pain in mouse knee joints.
Topics: Acute Disease; Amidohydrolases; Animals; Arthralgia; Benzamides; Carbamates; Carrageenan; Endocannab | 2014 |
Influence of a new 5-HT4 receptor partial agonist, YKP10811, on visceral hypersensitivity in rats triggered by stress and inflammation.
Topics: Animals; Benzamides; Carbamates; Colon; Disease Models, Animal; Female; Hyperalgesia; Inflammation; | 2014 |
A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis.
Topics: Activating Transcription Factor 3; Amidohydrolases; Anilides; Animals; Arachidonic Acids; Benzamides | 2015 |
The effect of FAAH, MAGL, and Dual FAAH/MAGL inhibition on inflammatory and colorectal distension-induced visceral pain models in Rodents.
Topics: Amidohydrolases; Animals; Benzodioxoles; Carbamates; Colon; Cyclohexanols; Inflammation; Male; Mice; | 2015 |
The C-terminal tails of 4,4'-diphenylmethane-bis(methyl) carbamate are essential for binding to receptor for advanced glycation end products to attenuate advanced glycation end products-induced inflammation and apoptosis responses in human umbilical vein
Topics: Apoptosis; Carbamates; Cell Adhesion; Cell Movement; Cell Survival; Cells, Cultured; Glycation End P | 2016 |
Modulation of macrophage functionality induced in vitro by chlorpyrifos and carbendazim pesticides.
Topics: Animals; Benzimidazoles; Carbamates; Cells, Cultured; Chlorpyrifos; Immunosuppression Therapy; Infla | 2016 |
Neuron-microglia interaction induced bi-directional cytotoxicity associated with calpain activation.
Topics: Animals; Calpain; Carbamates; Cell Survival; Cysteine Proteinase Inhibitors; Dipeptides; Enzyme Acti | 2016 |
The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.
Topics: Acetamides; Analgesics; Analgesics, Opioid; Animals; Arachidonic Acid; Arachidonic Acids; Carbamates | 2017 |
Targeting Kv7 channels in pain pathways.
Topics: Aminopyridines; Animals; Carbamates; Deafness; Epilepsy; Humans; Inflammation; KCNQ Potassium Channe | 2017 |
CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells in Lung
Topics: Adjuvants, Immunologic; Animals; Bronchial Hyperreactivity; Carbamates; CD8-Positive T-Lymphocytes; | 2017 |
Systemic and immunotoxicity of pristine and PEGylated multi-walled carbon nanotubes in an intravenous 28 days repeated dose toxicity study.
Topics: Animals; Biphenyl Compounds; Body Weight; Carbamates; Cells, Cultured; Erythrocytes; Female; Immunoe | 2017 |
Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain.
Topics: Amidohydrolases; Analgesia; Animals; Benzamides; Carbamates; Carrageenan; Disease Models, Animal; In | 2008 |
The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice.
Topics: Amidohydrolases; Analgesics; Animals; Anti-Inflammatory Agents; Arachidonic Acids; Benzamides; Capsa | 2010 |
Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats.
Topics: Analgesia; Animals; Anthracenes; Anticonvulsants; Carbamates; Feeding Behavior; Freund's Adjuvant; H | 2010 |
Antral gastritis and spasm; their clinical and surgical significance.
Topics: Carbamates; Gastritis; Humans; Inflammation; Organometallic Compounds; Spasm; Stomach; Stomach Disea | 1946 |
Effects of two oral antidiabetics, pioglitazone and repaglinide, on aconitase inactivation, inflammation and oxidative/nitrosative stress in tissues under alloxan-induced hyperglycemia.
Topics: Aconitate Hydratase; Administration, Oral; Alloxan; Animals; Blood Glucose; Body Weight; Carbamates; | 2011 |
Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability.
Topics: Amidohydrolases; Benzamides; Benzodioxoles; Caco-2 Cells; Cannabinoids; Carbamates; Cell Survival; E | 2012 |
M channel enhancers and physiological M channel block.
Topics: Aminopyridines; Animals; Bradykinin; Calcium; Carbamates; CHO Cells; Cricetinae; Cricetulus; Ganglia | 2012 |
Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system.
Topics: Amides; Amidohydrolases; Animals; Arachidonic Acids; Behavior, Animal; Benzamides; Carbamates; Disea | 2012 |
Development of a novel method for quantification of sterols and oxysterols by UPLC-ESI-HRMS: application to a neuroinflammation rat model.
Topics: Animals; Brain; Brain Chemistry; Carbamates; Chromatography, High Pressure Liquid; Inflammation; Lip | 2012 |
Amelioration of compound 4,4'-diphenylmethane-bis(methyl)carbamate on high mobility group box1-mediated inflammation and oxidant stress responses in human umbilical vein endothelial cells via RAGE/ERK1/2/NF-κB pathway.
Topics: Carbamates; Cell Line; Cell Movement; Coculture Techniques; Diabetes Mellitus; Endothelium, Vascular | 2013 |
[On the antiphlogistic effect of 3-phenylpropyl carbamate (MH 532), a new central muscle relaxant with tranquilizing properties].
Topics: Carbamates; Hypnotics and Sedatives; Inflammation; Muscle Relaxants, Central; Tranquilizing Agents; | 1959 |
[On the antiphlogistic effect of gamma-phenylpropyl carbamate and some of its derivatives].
Topics: Carbamates; Humans; Inflammation; Muscle Relaxants, Central; Tranquilizing Agents; Urea | 1960 |
Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors.
Topics: Amidohydrolases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Brain; Camphanes; Can | 2005 |
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.
Topics: Amidohydrolases; Animals; Benzamides; Carbamates; Chronic Disease; Disease Models, Animal; Enzyme In | 2006 |
Protein carbamylation links inflammation, smoking, uremia and atherogenesis.
Topics: Animals; Atherosclerosis; Blood Proteins; Carbamates; Cholesterol; Citrulline; Clinical Trials as To | 2007 |
'Multipurpose oxidase' in atherogenesis.
Topics: Animals; Apoptosis; Atherosclerosis; Carbamates; Cardiovascular Diseases; Cell Proliferation; Citrul | 2007 |
Inhibitory effect of bis[2-(E-2-octenoylamino)ethyl] disulfide and 2-(E-octenoylamino)ethyl carbamoylmethyl sulfide on various inflammation models.
Topics: Amides; Animals; Anti-Inflammatory Agents; Carbamates; Disulfides; Guinea Pigs; Inflammation; Male; | 1987 |
Desensitization to PAF-induced rat paw oedema by repeated intraplantar injections.
Topics: Animals; Carbamates; Carrageenan; Drug Tolerance; Edema; Inflammation; Injections; Injections, Intra | 1986 |
Synthesis and N.M.R. study of trans 2-phenoxycyclohexanol and some of its derivatives with potential antiinflammatory activity.
Topics: Amides; Amines; Animals; Anti-Inflammatory Agents; Carbamates; Chemical Phenomena; Chemistry; Cycloh | 1985 |
A study of the anti-inflammtory action of pyridinolcarbamate (Anginin).
Topics: Animals; Anti-Inflammatory Agents; Bradykinin; Burns; Capillary Permeability; Carbamates; Inflammati | 1969 |